DETAILS, FICTION AND CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY

In Section A, participants will acquire unique doses and schedules of oral ABBV-744 tablet to determine Harmless dosing routine. Further participants will be enrolled within the determined monotherapy dosign regimen. In Section B, individuals will obtain oral ruxolitinib and ABBV-744 will probably be given as "incorporate-on" therapy. In Phase C, i